Regression of established murine carcinoma metastases following vaccination with tumour-associated antigen peptides.
The cure of micrometastases following surgery is the major goal of cancer immunotherapy. We have recently isolated tumour-associated antigen (TAA) peptides, MUT 1 and MUT 2, derived from a mutated connexin 37 gap-junction protein, from the malignant 3LL-D122 murine lung carcinoma. We now report that synthetic MUT 1 or MUT 2 induces effective antitumour cytoxic T lymphocytes. Peptide vaccines protect mice from spontaneous metastases of 3LL-D122 tumours. Moreover, peptide vaccines reduce metastatic loads in mice carrying pre-established micrometastases. Tumour-specific immunity was primarily mediated by CD8+ T cells. This is the first evidence that peptide therapy may be effective in treatment of residual tumours and provides a rationale for the development of peptide vaccines as a modality for cancer therapy.
Mandelboim
O
O
Department of Cell Biology, Weizmann Institute of Science, Rehovot, Israel.
Vadai
E
E
Fridkin
M
M
Katz-Hillel
A
A
Feldman
M
M
Berke
G
G
Eisenbach
L
L
D000818:Animals; D000951:Antigens, Neoplasm / Q000276:immunology*; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D007167:Immunotherapy; D008175:Lung Neoplasms / Q000276:immunology / Q000556:secondary / Q000628:therapy*; D051379:Mice; D008810:Mice, Inbred C57BL; D009362:Neoplasm Metastasis / Q000517:prevention & control; D009842:Oligopeptides / Q000276:immunology*; D010446:Peptide Fragments / Q000138:chemical synthesis / Q000276:immunology*; D016019:Survival Analysis; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D014611:Vaccination
D000951:Antigens, Neoplasm; C096894:MUT 1 peptide; C096895:MUT 2 peptide; D009842:Oligopeptides; D010446:Peptide Fragments